Clinical heterogeneity of the LRRK2 G2019S mutation

Spiridon Papapetropoulos, Carlos Singer, Owen A Ross, Mathias Toft, Joseph L. Johnson, Matthew J. Farrer, Deborah C. Mash

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease. Objective: To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers. Design, Setting, and Participants: We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T. Main Outcome Measures: Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations. Results: Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants. Conclusions: The underlying disease mechanisms of LRRK2 G2019S-associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.

Original languageEnglish (US)
Pages (from-to)1242-1246
Number of pages5
JournalArchives of Neurology
Volume63
Issue number9
DOIs
StatePublished - 2006

Fingerprint

Leucine
Phosphotransferases
Mutation
Genes
Parkinson Disease
Parkinsonian Disorders
Repeats
Gene
Genetic Counseling
Parkinson's Disease
Myocardial Infarction
Outcome Assessment (Health Care)
Phenotype

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Papapetropoulos, S., Singer, C., Ross, O. A., Toft, M., Johnson, J. L., Farrer, M. J., & Mash, D. C. (2006). Clinical heterogeneity of the LRRK2 G2019S mutation. Archives of Neurology, 63(9), 1242-1246. https://doi.org/10.1001/archneur.63.9.1242

Clinical heterogeneity of the LRRK2 G2019S mutation. / Papapetropoulos, Spiridon; Singer, Carlos; Ross, Owen A; Toft, Mathias; Johnson, Joseph L.; Farrer, Matthew J.; Mash, Deborah C.

In: Archives of Neurology, Vol. 63, No. 9, 2006, p. 1242-1246.

Research output: Contribution to journalArticle

Papapetropoulos, S, Singer, C, Ross, OA, Toft, M, Johnson, JL, Farrer, MJ & Mash, DC 2006, 'Clinical heterogeneity of the LRRK2 G2019S mutation', Archives of Neurology, vol. 63, no. 9, pp. 1242-1246. https://doi.org/10.1001/archneur.63.9.1242
Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ et al. Clinical heterogeneity of the LRRK2 G2019S mutation. Archives of Neurology. 2006;63(9):1242-1246. https://doi.org/10.1001/archneur.63.9.1242
Papapetropoulos, Spiridon ; Singer, Carlos ; Ross, Owen A ; Toft, Mathias ; Johnson, Joseph L. ; Farrer, Matthew J. ; Mash, Deborah C. / Clinical heterogeneity of the LRRK2 G2019S mutation. In: Archives of Neurology. 2006 ; Vol. 63, No. 9. pp. 1242-1246.
@article{06d2a95e7dff440aaed6605f74bec6ef,
title = "Clinical heterogeneity of the LRRK2 G2019S mutation",
abstract = "Background: Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The {"}common{"} LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5{\%} of familial and 1{\%} of sporadic Parkinson disease. Objective: To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers. Design, Setting, and Participants: We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T. Main Outcome Measures: Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations. Results: Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants. Conclusions: The underlying disease mechanisms of LRRK2 G2019S-associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.",
author = "Spiridon Papapetropoulos and Carlos Singer and Ross, {Owen A} and Mathias Toft and Johnson, {Joseph L.} and Farrer, {Matthew J.} and Mash, {Deborah C.}",
year = "2006",
doi = "10.1001/archneur.63.9.1242",
language = "English (US)",
volume = "63",
pages = "1242--1246",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Clinical heterogeneity of the LRRK2 G2019S mutation

AU - Papapetropoulos, Spiridon

AU - Singer, Carlos

AU - Ross, Owen A

AU - Toft, Mathias

AU - Johnson, Joseph L.

AU - Farrer, Matthew J.

AU - Mash, Deborah C.

PY - 2006

Y1 - 2006

N2 - Background: Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease. Objective: To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers. Design, Setting, and Participants: We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T. Main Outcome Measures: Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations. Results: Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants. Conclusions: The underlying disease mechanisms of LRRK2 G2019S-associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.

AB - Background: Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease. Objective: To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers. Design, Setting, and Participants: We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T. Main Outcome Measures: Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations. Results: Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants. Conclusions: The underlying disease mechanisms of LRRK2 G2019S-associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.

UR - http://www.scopus.com/inward/record.url?scp=33748584315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748584315&partnerID=8YFLogxK

U2 - 10.1001/archneur.63.9.1242

DO - 10.1001/archneur.63.9.1242

M3 - Article

VL - 63

SP - 1242

EP - 1246

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -